It is known that cancer-related cognitive impairment (CRCI), which includes problems with memory, executive function, attention, and processing speed, is an important issue for patients. Yet limitations in previous studies have left several questions about when and why it occurs and who is most likely to develop the condition. CRCI can be related to disease, surgery, chemotherapy, radiation, hormone therapy, and immunotherapy. It negatively impacts quality of life (QOL).
Assessing the patient’s perspective is an important aspect of CRCI, particularly because some neuropsychological tests cannot detect CRCI complaints. Patient-reported outcomes (PROs) are ideal because of the lack of practice effects and clinical adaptability. In a recent research published in a renowned Journal of Clinical Oncology, scientists compared cognitive difficulties among 581 breast cancer patients treated at…
